drugset / Trial / NCT07413978

A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome

NCT07413978

Phase 1/2 Recruiting 36 enrolled Changchun Tuohua Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Primary Objective: To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection in the treatment of moderate/severe acute respiratory distress syndrome.Secondary Objectives: To explore the efficacy and appropriate dosage of human umbilical cord mesenchymal stem cell injection in the treatment of moderate/severe acute respiratory distress syndrome.Exploratory Objective: To explore the immunogenicity and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of a single dose of human umbilical cord mesenchymal stem cell injection in patients with moderate/severe acute respiratory distress syndrome.

Timeline

Start
2025-04-25
Primary completion
2027-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject human umbilical cord mesenchymal stem cells Cell therapy 5e+07 cells Other
Subject human umbilical cord mesenchymal stem cells Cell therapy 1e+08 cells Other
Subject human umbilical cord mesenchymal stem cells Cell therapy 1.5e+08 cells Other
Subject human umbilical cord mesenchymal stem cells Cell therapy 2e+08 cells Other